Biogen Idec Inc., the world’s biggest maker of multiple sclerosis drugs, said a European regulatory decision on its new pill will be delayed until the second half of the year after a patent on the medicine was extended.
Rigel Pharmaceuticals Inc., a drugmaker with no products on the market, fell in early trading after its experimental rheumatoid arthritis medicine being developed with AstraZeneca Plc showed mixed results in a trial.
Biogen Idec Inc. won European Union backing for Tecfidera, one of the first therapies for multiple sclerosis available in an easy-to-take pill that analysts say may generate $3.25 billion in annual sales.
Incyte Corp., a maker of cancer and autoimmune drugs, climbed for a second trading day after a study showed improvement for patients on the experimental rheumatoid arthritis treatment it’s developing with Eli Lilly & Co.
Vertex Pharmaceuticals Inc., maker of the hepatitis C drug Incivek, has received interest from other companies to collaborate on tests of one of its experimental medicines for the liver disease, Chief Executive Officer Jeffrey Leiden said.